ATE288264T1 - Kombinationspräparate zur behandlung von erkrankungen, die mit angiogenese verbunden sind - Google Patents

Kombinationspräparate zur behandlung von erkrankungen, die mit angiogenese verbunden sind

Info

Publication number
ATE288264T1
ATE288264T1 AT00903832T AT00903832T ATE288264T1 AT E288264 T1 ATE288264 T1 AT E288264T1 AT 00903832 T AT00903832 T AT 00903832T AT 00903832 T AT00903832 T AT 00903832T AT E288264 T1 ATE288264 T1 AT E288264T1
Authority
AT
Austria
Prior art keywords
angiogenesis
treatment
diseases associated
combination products
formation
Prior art date
Application number
AT00903832T
Other languages
English (en)
Inventor
Peter David Davis
Original Assignee
Angiogene Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogene Pharm Ltd filed Critical Angiogene Pharm Ltd
Application granted granted Critical
Publication of ATE288264T1 publication Critical patent/ATE288264T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
AT00903832T 1999-02-16 2000-02-15 Kombinationspräparate zur behandlung von erkrankungen, die mit angiogenese verbunden sind ATE288264T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903404.3A GB9903404D0 (en) 1999-02-16 1999-02-16 Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
PCT/GB2000/000511 WO2000048591A1 (en) 1999-02-16 2000-02-15 Combinations for the treatment of diseases involving angiogenesis

Publications (1)

Publication Number Publication Date
ATE288264T1 true ATE288264T1 (de) 2005-02-15

Family

ID=10847791

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00903832T ATE288264T1 (de) 1999-02-16 2000-02-15 Kombinationspräparate zur behandlung von erkrankungen, die mit angiogenese verbunden sind

Country Status (21)

Country Link
US (2) US7087627B1 (de)
EP (1) EP1161235B1 (de)
JP (1) JP4708569B2 (de)
KR (2) KR20070034642A (de)
CN (1) CN1344159B (de)
AT (1) ATE288264T1 (de)
AU (1) AU775242B2 (de)
BR (1) BR0008254A (de)
CA (1) CA2362281C (de)
DE (1) DE60017878T2 (de)
DK (1) DK1161235T3 (de)
ES (1) ES2237407T3 (de)
GB (1) GB9903404D0 (de)
HK (1) HK1040919B (de)
IL (2) IL144847A0 (de)
MX (1) MXPA01008245A (de)
NO (1) NO20013966L (de)
NZ (1) NZ513429A (de)
PT (1) PT1161235E (de)
WO (1) WO2000048591A1 (de)
ZA (1) ZA200106688B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
EE200200565A (et) 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
WO2002009700A1 (en) 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy
US20050153939A1 (en) 2003-09-10 2005-07-14 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
AU2002216029B2 (en) * 2000-10-27 2006-01-05 Pfizer, Inc. A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
EP1351573A4 (de) * 2000-12-22 2007-03-28 Bristol Myers Squibb Co Verfahren zur modulation des tumorwachtums und der metastasierung
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
NZ575466A (en) * 2001-07-13 2011-01-28 Oxigene Inc Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
AU2008202468B2 (en) * 2001-07-13 2011-08-11 Oxigene, Inc. Compositions and Methods of Administering Tubulin Binding Agents for the Treatment of Ocular Diseases
EP1287854B1 (de) * 2001-08-30 2005-11-30 Cancer Research Technology Limited Antikrebs-Kombinationen aus DMXAA und Paclitaxel oder Docetaxel
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
WO2008147445A2 (en) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
US20100087370A1 (en) * 2007-02-14 2010-04-08 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
CA2703283C (en) 2007-11-21 2016-01-12 Oxigene, Inc. Method for treating hematopoietic neoplasms
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
JP2018523712A (ja) 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. 腫瘍に対する免疫調節療法を向上させる為のｖｄａｓの使用
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5533094A (en) 1992-11-27 1994-06-22 Wellcome Foundation Limited, The Enzyme inhibitors
US5554638A (en) * 1993-05-24 1996-09-10 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5424447A (en) * 1993-07-07 1995-06-13 The Medical College Of Wisconsin Research Foundation, Inc. Heme binding compounds and use thereof
GB9320484D0 (en) * 1993-10-05 1993-11-24 Wellcome Found Pharmaceutical combinations
AU4515896A (en) * 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
AU2213197A (en) 1996-03-05 1997-09-22 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore

Also Published As

Publication number Publication date
ES2237407T3 (es) 2005-08-01
CA2362281A1 (en) 2000-08-24
BR0008254A (pt) 2001-11-06
NZ513429A (en) 2003-10-31
CN1344159A (zh) 2002-04-10
WO2000048591A1 (en) 2000-08-24
PT1161235E (pt) 2005-05-31
MXPA01008245A (es) 2002-10-23
JP4708569B2 (ja) 2011-06-22
IL144847A (en) 2006-10-31
KR20010102038A (ko) 2001-11-15
AU775242B2 (en) 2004-07-22
US7087627B1 (en) 2006-08-08
NO20013966D0 (no) 2001-08-15
IL144847A0 (en) 2002-06-30
EP1161235A1 (de) 2001-12-12
EP1161235B1 (de) 2005-02-02
DE60017878D1 (de) 2005-03-10
NO20013966L (no) 2001-10-15
DK1161235T3 (da) 2005-05-09
CN1344159B (zh) 2011-09-28
GB9903404D0 (en) 1999-04-07
KR20070034642A (ko) 2007-03-28
AU2559000A (en) 2000-09-04
HK1040919B (zh) 2005-05-13
JP2002537251A (ja) 2002-11-05
ZA200106688B (en) 2002-08-14
US20060198846A1 (en) 2006-09-07
HK1040919A1 (en) 2002-06-28
DE60017878T2 (de) 2006-01-26
CA2362281C (en) 2008-11-18

Similar Documents

Publication Publication Date Title
ATE288264T1 (de) Kombinationspräparate zur behandlung von erkrankungen, die mit angiogenese verbunden sind
KR960703603A (ko) 프로게스테론형 제제 및 산화질소 합성효소 기질 및 산화질소 공여물질의 배합물을 사용한 자간전증 및 조산의 치료(Combination of a Progestational Agent and a Nitric Oxide Synthase substrate and/or Donor for the Treatment of Preeclampsia and Preterm Labor)
PT915898E (pt) Forma i cristalina de claritromicina
DE69811867T2 (de) Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten
BR9306371A (pt) Composições refrescantes
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
FI955315A (fi) HIV:n proteaasin inhibiittoreita, jotka ovat käyttökelpoisia AIDS&#39;n hoitoon
NZ513629A (en) C-21 modified epothilones
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
CO5001019A1 (es) Composicion emulsionable para la represion de insectos, que se deriva del tipo de fenilpirazoles sustituidos en posi- cion 1, y no favorecen la formacion de cristales
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
ES507236A0 (es) Un procedimiento para preparar una composicion farmaceutica para aplicacion topica, empleada en el tratamiento del acne.
SE9604348D0 (sv) Användning av hydroxyguanidiner
DE59300631D1 (de) Biologisch abbaubare, wässrige Dispersionen.
MXPA03001455A (es) Compuestos de pirazol, composiciones farmaceuticas y metodos para modular o inhibir la actividad del amiloide-beta-peptido asociado a reticulo endoplasmico y l-3-hidroxiacil-coa-deshidrogenasa.
DK0556322T3 (da) Aminosulfonylurinstof-ACAT-inhibitorer
DE69316754D1 (de) Schrittweise entfernung von monosacchariden vom reduzierenden ende von oligosacchariden und verwendungen davon
BR0116205A (pt) 2-piridonas antimicrobianas, suas composições e usos
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
ATE209647T1 (de) Pyridiniumsalze und ihre verwendung zur bekämpfung von helicobacter-bakterien
AU2001230243A1 (en) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
ATE323493T1 (de) Gesteuerte freisetzung von antidepressiva
PT1232173E (pt) Derivados do acido fusidico
GB0007239D0 (en) Use
ES2185154T3 (es) Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de la demencia.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1161235

Country of ref document: EP

REN Ceased due to non-payment of the annual fee